Endocrine Abstracts

Introduction: Patients with type 1 diabetes mellitus (DM1) present a high prevalence of autoimmune associated diseases. Recently, we described a prevalence of latent pernicious anemia (LPA) of 12.4% in DM1.Objectives: A 5-year follow-up study of a cohort of DM1 patients in order to evaluate the evolution of biochemical markers of LPA, defined as a serum pepsinogen I (PI) concentration below normal limits.Material and methods: One h...

Non-functioning pituitary adenomas (NFPA) are the most common pituitary tumours. They usually come to medical attention because of a mass effect and/or hypopituitarism. Tumour shrinkage during therapy with either dopamine agonists (DA) or somatostatin analogues (SSA) has been previously reported in some cases; however, response of NFPA to medical treatment is still poor and unpredictable. Our aim was to explore the molecular mechanisms underlying this lack of efficacy through ...

Introduction: This study aimed to determine the timeframe to achieve hormonal normalization considering dosing patterns of Somatuline Autogel (SOM, lanreotide) used in clinical practice.Methods: From March 2013 to October 2013 clinical data from 62 patients with active acromegaly treated with SOM for &gE;4 months who achieved hormonal control (GH levels <2.5 ng/ml and/or normalised IGF1 on &gE;two evaluations) at 17 Spanish hospitals were collected i...

Introduction: The autosomal dominant multiple endocrine neoplasia type 1 (MEN1), characterized by parathyroid hyperplasia (PH), neuroendocrine digestive tumours (NET) and pituitary adenomas (PA), is due to mutations in the tumor suppressor gene MEN1 encoding a 610-amino acid protein, menin. Guidelines recommend MEN1 mutational analysis in index cases with two or more MEN1-associated tumours, in first-degree relatives of mutation carriers and when clinical dat...

Introduction: Endogenous Cushing’s syndrome (CS) is a rare, infradiagnosed and severe disease that carries high morbidity and mortality. Delays in treatment initiation reduce reversibility of symptoms and increase mortality rate. Current gold standard for screening, 24 h urinary free cortisol, has a low reproducibility and specificity, and sampling is complicated. Midnight salivary cortisol (MSVC) determination is considered an easy and cheap test. We intend to assess its...

Pegvisomant (peg) is an effective treatment for acromegaly.Aim: To investigate the prevalence of escape and the incidence of lipodystrophy with peg treatment.Methods: Multicenter retrospective study. Escape was defined as loss of control in patients previously controlled under a stable dose of peg, without any other treatment change. Lipodystrophy was defined as either hypertrophy or atrophy of subcutaneous tissue in areas of drug ...

Pharmacologic treatment of acromegaly is currently based upon assay-error strategy in which first generation somatostatin analogs (SSA) is the first-line treatment. However, about 50% of patients do no respond adequately to SSA. We aimed to evaluate the potential usefulness of including studies of molecular markers identifying poor response to SSA for prescription of pharmacologic treatment in acromegalic patients in which SSA was prescribed before surgical therapy.<p clas...

Medical treatment of acromegaly is currently performed through a trial-error manner using somatostatin receptor ligands (SRLs) as first-line drugs. Average SRLs response is seen in 50% of cases; subsequent drugs are indicated following clinical judgement. Some biomarkers either before or after surgical failure have been reported to predict SRLs response, including intensity in T2 weighted MRI, short acute octreotide test (sAOT), and different molecules such as SST2 and E-cadhe...